NICE dismisses GSK's Tyverb appeal but throws off-label Herceptin lifeline
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has dismissed GlaxoSmithKline's appeal against the institute's final draft guidance rejecting Tyverb (lapatinib) for some breast cancer patients, except in the context of clinical trials.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.